세계의 췌장암 진단 시장 - 산업 규모, 동향, 기회, 예측, 검사 유형별, 암 유형별, 최종 사용자별, 지역별, 경쟁(2020-2030년)
Pancreatic Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Cancer Type, By End User, By Region and Competition, 2020-2030F
상품코드:1763910
리서치사:TechSci Research
발행일:2025년 06월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 췌장암 진단 시장 규모는 2024년에 28억 7,000만 달러로 평가되었고, 2030년에는 43억 2,000만 달러에 이를 것으로 예상되며, 예측 기간 중 CAGR은 7.05%를 나타낼 전망입니다.
이 시장은 췌장암의 이환율 증가, 저침습 진단 기술에 대한 수요 증가, 연구개발 투자 증가에 의해 기세를 늘리고 있습니다. 영향에 대한 인식이 높아짐에 따라 효과적인 진단 툴에 대한 수요가 크게 증가하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
28억 7,000만 달러
시장 규모 : 2030년
43억 2,000만 달러
CAGR : 2025-2030년
7.05%
급성장 부문
혈액 검사
최대 시장
북미
시장 성장 촉진요인
췌장암 이환율 상승
주요 시장 과제
비특이적 증상에 의한 진단 지연
주요 시장 동향
조기 발견과 맞춤형 의료의 중시
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 췌장암 진단 시장 전망
시장 규모와 예측
금액별
시장 점유율·예측
검사 유형별(진단 영상 검사, 생검, 혈액 검사, 간 기능 검사, 기타)
암 유형별(외분비암, 선암종, 편평세포암, 콜로이드 암종, 기타)
최종 사용자별(병원 및 진료소, 진단센터, 기타)
지역별
기업별(2024년)
제품 맵
검사 유형별
암 유형별
최종 사용자별
지역별
제6장 북미의 췌장암 진단 시장 전망
시장 규모와 예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 췌장암 진단 시장 전망
시장 규모와 예측
시장 점유율·예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 췌장암 진단 시장 전망
시장 규모와 예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 췌장암 진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 췌장암 진단 시장 전망
시장 규모와 예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
합병과 인수
제품 출시
제13장 세계의 췌장암 진단 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Siemens Healthineers AG
Myriad Genetics, Inc.
Pfizer, Inc
Novartis AG
AstraZeneca plc
Immunovia AB
Laboratory Corporation of America Holdings
Abbott Laboratories
Agilent Technologies, Inc.
Thermo Fisher Scientific Inc.
제16장 전략적 제안
제17장 기업 소개와 면책사항
KTH
영문 목차
영문목차
The Global Pancreatic Cancer Diagnostics Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.32 billion by 2030, registering a CAGR of 7.05% during the forecast period. The market is gaining momentum due to the growing incidence of pancreatic cancer, increased demand for minimally invasive diagnostic techniques, and rising investments in R&D. Pancreatic cancer remains one of the deadliest forms of cancer due to its silent progression and late-stage detection. As awareness grows around early screening and its impact on survival outcomes, the demand for effective diagnostic tools has increased significantly. Moreover, the aging global population-particularly those aged 60 and above-has contributed to a higher incidence of pancreatic cancer, further driving demand for early detection technologies and diagnostic advancements.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.87 Billion
Market Size 2030
USD 4.32 Billion
CAGR 2025-2030
7.05%
Fastest Growing Segment
Blood Tests
Largest Market
North America
Key Market Drivers
Rising Incidence of Pancreatic Cancer
The rising global incidence of pancreatic cancer serves as a major catalyst for the growth of the pancreatic cancer diagnostics market. According to the American Cancer Society, around 66,440 individuals in the U.S. are expected to be diagnosed with pancreatic cancer in 2024, with an estimated 51,750 fatalities. This high mortality rate emphasizes the urgency for improved diagnostic solutions. Globally, the increasing burden of pancreatic cancer is influenced by aging populations, evolving lifestyles, and environmental risk factors. As the disease is often diagnosed at a late stage due to its aggressive progression, healthcare systems are focusing more on developing advanced diagnostics that enable early and accurate detection.
Key Market Challenges
Late Diagnosis Due to Non-Specific Symptoms
One of the primary obstacles in pancreatic cancer diagnostics is the difficulty in early detection due to vague and non-specific symptoms such as abdominal discomfort, unexplained weight loss, and jaundice. These symptoms often resemble those of less severe conditions, causing significant delays in diagnosis. As a result, patients are frequently diagnosed at advanced stages when treatment options are limited. Although novel tools like the PAC-MANN blood test-showing 85% accuracy when used alongside CA 19-9-present promising results, broader implementation remains hindered by the need for further clinical validation and regulatory approvals.
Key Market Trends
Emphasis on Early Detection and Personalized Medicine
A prominent trend shaping the pancreatic cancer diagnostics market is the increasing emphasis on early detection and the integration of personalized medicine. Advances in diagnostic technologies, including experimental blood tests with up to 97% accuracy for stage 1 and 2 cancers, highlight the potential for improving outcomes through early diagnosis. Simultaneously, personalized approaches based on genetic profiling are gaining traction. Genomic testing enables identification of actionable mutations, allowing clinicians to customize treatment plans. Recent studies indicate that nearly one-third of patients with advanced pancreatic cancer had their treatments modified based on such insights, reinforcing the growing importance of precision diagnostics.
Key Market Players
Siemens Healthineers AG
Myriad Genetics, Inc.
Pfizer, Inc
Novartis AG
AstraZeneca plc
Immunovia AB
Laboratory Corporation of America Holdings
Abbott Laboratories
Agilent Technologies, Inc.
Thermo Fisher Scientific Inc.
Report Scope:
In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Pancreatic Cancer Diagnostics Market, By Test Type:
Diagnostic Imaging Tests
Biopsy
Blood Tests
Liver Function Tests
Others
Pancreatic Cancer Diagnostics Market, By Cancer Type:
Exocrine
Adenocarcinoma
Squamous Cell Carcinoma
Colloid Carcinoma
Others
Pancreatic Cancer Diagnostics Market, By End User:
Hospitals & Clinics
Diagnostic Centers
Others
Pancreatic Cancer Diagnostics Market, By Region:
North America
United States
Mexico
Canada
Europe
France
Germany
United Kingdom
Italy
Spain
Asia-Pacific
China
India
South Korea
Japan
Australia
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Diagnostics Market.
Available Customizations:
Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pancreatic Cancer Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, Others)
5.2.1.1. By Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Product Map
5.3.1. By Test Type
5.3.2. By Cancer Type
5.3.3. By End User
5.3.4. By Region
6. North America Pancreatic Cancer Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Cancer Type
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Cancer Type
6.3.1.2.3. By End User
6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Cancer Type
6.3.2.2.3. By End User
6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Cancer Type
6.3.3.2.3. By End User
7. Europe Pancreatic Cancer Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Cancer Type
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Pancreatic Cancer Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Cancer Type
7.3.1.2.3. By End User
7.3.2. Germany Pancreatic Cancer Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Cancer Type
7.3.2.2.3. By End User
7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Test Type
7.3.3.2.2. By Cancer Type
7.3.3.2.3. By End User
7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Cancer Type
7.3.4.2.3. By End User
7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Cancer Type
7.3.5.2.3. By End User
8. Asia-Pacific Pancreatic Cancer Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Cancer Type
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Cancer Type
8.3.1.2.3. By End User
8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Cancer Type
8.3.2.2.3. By End User
8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Cancer Type
8.3.3.2.3. By End User
8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Cancer Type
8.3.4.2.3. By End User
8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Cancer Type
8.3.5.2.3. By End User
9. South America Pancreatic Cancer Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Cancer Type
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Cancer Type
9.3.1.2.3. By End User
9.3.2. Argentina Pancreatic Cancer Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Cancer Type
9.3.2.2.3. By End User
9.3.3. Colombia Pancreatic Cancer Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Cancer Type
9.3.3.2.3. By End User
10. Middle East and Africa Pancreatic Cancer Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Cancer Type
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pancreatic Cancer Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Cancer Type
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Cancer Type
10.3.2.2.3. By End User
10.3.3. UAE Pancreatic Cancer Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Cancer Type
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis
